Novartis Halts ALS Drug Development After Mid-Stage Trial Failure
The study enrolled 251 patients and missed both main and secondary goals, adding to investor scrutiny of Novartis's pipeline.
8 Articles
8 Articles
New Disappointment in the Search for a Cure for ALS: Novartis Halts Development of Experimental Drug
Pharmaceutical giant Novartis has halted development of its experimental drug VHB937 for the treatment of amyotrophic lateral sclerosis (ALS), one of the most severe progressive neurological diseases. The drug failed to slow the progression of the disease any more than a placebo in a clinical trial. It is the latest setback in the decades-long search for a more effective treatment for the disease, in which nerve cells that control muscles gradua…
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of its experimental drug for the treatment of amyotrophic lateral sclerosis (ALS) after the drug was not shown to be more effective than placebo in slowing the progression of the disease in a phase II clinical trial.
(Teleborsa) - Novartis has stopped the development of an experimental drug for the treatment of amiotrophic lateral sclerosis, pathology with rapid progression leading to paralysis, difficulty swallowing and problems...
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
